Highlights Passage Bio, Inc.

Equities

PASG

US7027121000

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.94 ^USD	+3.18%		+2.62%	-6.93%

Jun. 12	Transcript : Passage Bio, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM
May. 15	Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities	Dec. 20	CI
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Passage Bio, Inc. Announces New Interim Safety, Biomarker, and Survival Data from Cohorts 1-4 in Imagine-1 Clinical Study	23-08-07	CI
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Passage Bio, Inc. Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023	23-02-24	CI
Passage Bio, Inc. Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study	22-12-14	CI
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Earnings Flash (PASG) PASSAGE BIO Reports Q3 Loss $-0.49, vs. Street Est of $-0.77	22-11-10	MT
Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations	22-08-11	CI
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Passage Bio, Inc. Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy	22-06-08	CI
Passage Bio, Inc. Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study At ASGCT 25Th Annual Meeting	22-05-18	CI
Earnings Flash (PASG) PASSAGE BIO Reports Q1 Loss $-0.79, vs. Street Est of $-0.92	22-05-16	MT
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Passage Bio, Inc. Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease	22-03-29	CI
Passage Bio, Inc. Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease	22-03-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Passage Bio, Inc.

Equities

PASG

US7027121000

Highlights

Filters